^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KLLN (Killin P53 Regulated DNA Replication Inhibitor)

    i
    Other names: KLLN, Killin P53 Regulated DNA Replication Inhibitor, Killin, Killin P53-Regulated DNA Replication Inhibitor, KILLIN, CWS4
    Associations

    News

    Trials
    5ms
    Genetic Variants Associated with Breast Cancer Are Detected by Whole-Exome Sequencing in Vietnamese Patients. (PubMed, Diagnostics (Basel))
    This is the first WES study to identify BC-associated genetic variants in Vietnamese patients, providing a comprehensive database of BC susceptibility gene variants. We suggest using WES as a tool to identify genetic variants in BC patients for risk prediction and treatment guidance.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • NF1 (Neurofibromin 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PMS2 (PMS1 protein homolog 2) • MSH3 (MutS Homolog 3) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • CASP8 (Caspase 8) • WRN (WRN RecQ Like Helicase) • CHD8 (Chromodomain Helicase DNA Binding Protein 8) • RECQL (RecQ Like Helicase) • KLLN (Killin P53 Regulated DNA Replication Inhibitor) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • RB1CC1 (RB1 Inducible Coiled-Coil 1) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit) • XRCC3 (X-Ray Repair Cross Complementing 3) • ACVR1B (Activin A Receptor Type 1B)
    almost2years
    LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B. (PubMed, J Exp Clin Cancer Res)
    Overall, the LINC00606/miR-486-3p/TCF12/ATP11B axis is involved in the regulation of GBM progression and plays a role in tumor regulation at transcriptional and post-transcriptional levels primarily through LINC00606 sponging miR-486-3p and targeted binding to ATP11B. Therefore, our research on the regulatory network LINC00606 could be a novel therapeutic strategy for the treatment of GBM.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) • KLLN (Killin P53 Regulated DNA Replication Inhibitor) • MIR486-1 (MicroRNA 486-1) • TCF12 (Transcription Factor 12)
    2years
    EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN. (PubMed, Adv Sci (Weinh))
    Such inhibition on PDAC progression is also achieved through increasing H3K4me1 level by GSK-LSD1, a selective inhibitor of lysine-specific demethylase 1 (LSD1). Taken together, these findings reveal a new mechanism underlying PDAC progression and provide potential therapeutic targets for PDAC treatment.
    Journal
    |
    KMT2D (Lysine Methyltransferase 2D) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    2years
    Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9-mediated genome engineering in HAP1 cells mimicking cancer profiles. (PubMed, Life Sci Alliance)
    As in HAP1 cells, the deletion contributed to similar gene expression patterns among cancer patients despite interindividual differences. Our findings suggest that the unintended deletion of 10q23.31 can confound CRISPR-Cas9 studies and underscore the importance to assess unintended genomic changes in CRISPR-Cas9-modified cells, which could impact cancer research.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    almost3years
    IN SEARCH FOR GENOMIC AND TRANSCRIPTOMIC PREDICTORS OF RELAPSE IN PEDIATRIC T-ALL (EHA 2023)
    CNAs reflect high genomic heterogeneity of T-ALL and seem suboptimal candidates for relapse predictors. Gene expression at diagnosis efficiently discriminates RR vs. non-RR and enabled to develop an 11-gene classifier which needs to be independently validated.
    Clinical
    |
    EML4 (EMAP Like 4) • CDK6 (Cyclin-dependent kinase 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    over3years
    LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. (PubMed, Cell Death Dis)
    The clinical samples of TNBC confirmed SEAS1 was correlated inversely with lymphatic and distant metastasis. In conclusion, our findings reveal a novel pathway for TNBC progression via SMAD3/lncRNA SEAS1/miR-3940-3p/KLLN axis, and suggest that SEAS1 may serve as a potential biomarker and therapeutic target for TNBC.
    Journal
    |
    KLLN (Killin P53 Regulated DNA Replication Inhibitor) • SMAD3 (SMAD Family Member 3)
    over3years
    Detecting Early-Stage Oral Cancer from Clinically Diagnosed Oral Potentially Malignant Disorders by DNA Methylation Profile. (PubMed, Cancers (Basel))
    Furthermore, when compared with cytology testing, the panel could accurately detect oral cancer. The present methylated gene panel may serve as a novel biomarker for oral cancer.
    Journal • Epigenetic controller
    |
    GSTP1 (Glutathione S-transferase pi 1) • CASP8 (Caspase 8) • TP73 (Tumor Protein P73) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    over3years
    t(10;12)(q24;q15): A new cytogenetic marker in hematological malignancies. (PubMed, Cancer Genet)
    We reviewed the literature to determine whether this chromosome abnormality had previously been described in other hematological patients and found two cases: an aggressive T-cell lymphoblastic lymphoma (T-LBL) and a case of transformed chronic myeloproliferative syndrome (CMS), in both of which t(10;12)(q24;q15) was also the only karyotype change. The clinical evolution of all four cases suggested that t(10;12)(q24;q15) is associated with a poor outcome in oncohematological patients.
    Journal
    |
    HMGA2 (High mobility group AT-hook 2) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    almost4years
    Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. (PubMed, Orphanet J Rare Dis)
    This study expands previously reported findings in other PHTS population studies and makes new contributions regarding clinical and molecular aspects of PHTS, which are useful for translation to the clinic and for new research lines.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    4years
    p53-mediated G1 arrest requires the induction of both p21 and Killin in human colon cancer cells. (PubMed, Cell Cycle)
    Immunoprecipitation studies indicated that Killin may directly bind to proteasome subunits, thereby disrupting proteasomal degradation of p21. Together, these results demonstrate that Killin is involved in multiple cell cycle checkpoint controls, including p53-mediated G1 arrest.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    |
    TP53 expression
    over4years
    circAMOTL1L Suppresses Renal Cell Carcinoma Growth by Modulating the miR-92a-2-5p/KLLN Pathway. (PubMed, Oxid Med Cell Longev)
    Conclusively, our findings demonstrate that circAMOTL1L has an antioncogenic role in RCC growth by modulating the miR-92a-2-5p-KLLN pathway. Thus, targeting the novel circAMOTL1L-miR-92a-2-5p-KLLN regulatory axis might provide a therapeutic strategy for RCC.
    Journal
    |
    KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    over4years
    Genetic Analysis Reveals the Important Role of the APC Gene in Clear Cell Renal Cell Carcinoma. (PubMed, Anticancer Res)
    In addition to VHL inactivation, promoter methylation of APC may be a universal pathognomonic event in the tumorigenesis of RCC and a candidate diagnostic and therapeutic biomarker.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • VHL (von Hippel-Lindau tumor suppressor) • APC (APC Regulator Of WNT Signaling Pathway) • CASP8 (Caspase 8) • DAPK1 (Death Associated Protein Kinase 1) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
    |
    VHL mutation